Chongqing Zhien Pharmaceutical Co., Ltd. "mesylate", the first imitated drug in the treatment of bronchial asthma, has obtained the new drug certificate

The raw materials and granules of mesilast, a drug for treating bronchial asthma, developed by Chongqing Zhien Pharmaceutical Co., Ltd., obtained the new drug certificate and production approval issued by the State Food and drug administration, and passed GMP certification It has realized the first domestic imitation of "mesylate" API and its granules, and filled in the domestic market gap "Suplatast tosilate" granule is a Th2 cytokine inhibitor developed by Japan Dapeng Taiho company It was listed in Japan in 1995 and is mainly used in the treatment of bronchial asthma, allergic dermatitis and allergic rhinitis "Mesylate" developed by Chongqing Zhien Pharmaceutical Co., Ltd breaks through the key technology of esterification, shortens the whole synthesis process, improves the reaction yield and reduces the production cost At the same time, it solves the problems of strong hygroscopicity and easy degradation in the preparation production process, and makes the product quality more stable According to statistics, in 2011, the global cost of asthma treatment reached 5.48 billion US dollars In China, the average annual medical cost of each asthma patient is more than 3000 yuan At present, mesylate granules are only listed in Japan, and there is no import in China Chongqing Zhien Pharmaceutical Co., Ltd has achieved the industrialization of mesylate granules by the end of 2013 through technical breakthrough, and is expected to increase the output value by 50 million yuan in 2014 After the drug is put on the market, it will not only provide safe and effective drugs for the majority of patients with asthma in China, but also greatly reduce the cost of medication Founded in 2001, Zhien Pharmaceutical Co., Ltd is a new pharmaceutical enterprise integrating R & D, production, sales and market At present, it has formed an industrial cluster with Chongqing Zhien Pharmaceutical Co., Ltd as the core, including a series of medical and health service platforms such as Zhien Hospital Management Co., Ltd., Chongqing Liangjiang pharmaceutical R & D Center Co., Ltd., Chongqing Zhien Pharmaceutical Sales Co., Ltd., Chongqing Jiang'an pharmacy chain Co., Ltd The annual investment in new drug R & D and technology improvement of Zhien pharmaceutical industry accounts for more than 5% of the sales revenue At present, it has obtained 33 new drug certificates, 32 clinical approvals and 51 production approvals It has applied for dozens of national invention patents, including 2 foreign patent authorizations and 11 domestic patent authorizations At present, the main products of the company are tropisetron hydrochloride, orlistat, donepezil hydrochloride, ropinilo hydrochloride, mesylate, cilostazol, etc 2 - (4 - (3-ethoxy-2-hydroxypropyl) phenyl carbamoyl) ethyl) dimethyl sulfonium p-toluenesulfonate CAS No 94055-76-2 formula c16h26no4sc7h7o3s; c23h